Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq:HCM) said on Wednesday that they will expand their global collaboration to evaluate the safety and efficacy of Innovent's Tyvyt (sintilimab injection) in combination with Chi-Med's surufatinib in patients with advanced solid tumours.
This builds on their existing global collaboration agreement on sintilimab in combination with Chi-Med's highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor, fruquintinib.
Clinical studies with this new combination will be conducted both in the US and in China.
Tyvyt is a type of immunoglobulin G4 monoclonal antibody which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells.
Surufatinib is a novel, oral drug candidate that selectively inhibits the tyrosine kinase activity associated with VEGFR and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, as well as CSF-1R, which regulates tumor-associated macrophages, promoting the body's immune response against tumour cells.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886